Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?
Mené sur 135 patients atteints d'une leucémie lymphoïde chronique à lymphocytes B (âge : au moins 18 ans), cet essai multicentrique de phase II évalue l’efficacité, du point de vue du taux de réponse complète, et la toxicité d'un traitement d'induction combinant obinutuzumab et ibrutinib pendant 9 mois
The approval of targeted drugs set in place new treatment frameworks for patients with chronic lymphocytic leukaemia. Among these new drugs, ibrutinib has gained a wide acceptance as a first-line or second-line therapy. Ibrutinib is used as a continuous regimen until unacceptable toxicity or progression of disease.